Who We Are

The New Jersey Life Sciences Vendors Alliance (NJLSVA) is a coalition of businesses, individuals and academia who provide goods and services to New Jersey’s life sciences companies.

The NJLSVA was founded to educate suppliers on trends in industry procurement and public policy that affects the life sciences industry.

Monthly Archives: June 2015

HINJ Presents Online Compendium of Member Companies’ Corporate Social Responsibility, Sustainability Activities

hinj_logo_high_resNew Brunswick, NJ, June 21, 2015 ―The HealthCare Institute of New Jersey (HINJ) presents an online portal to HINJ member companies’ myriad corporate social responsibility (CSR) activities, including their corporate philanthropy, patient outreach initiatives and sustainability/green practices.

Launched in November 2014, the online portal — “HINJ Members’ CSR Activities” — is accessible by clicking on the second tab on the HINJ homepage’s Corporate Social Responsibility menu. Continue reading

FDA Takes Action to Protect Consumers from Dangerous Counterfeit Medicines and Devices Sold Online

FDA blueWashington, DC, June 21, 2015 ― The U.S. Food and Drug Administration, in partnership with international regulatory and law enforcement agencies, took action this week against more than 1,050 websites that illegally sell potentially dangerous, unapproved prescription medicines and medical devices to consumers.

These actions include the issuance of regulatory warnings to the operators of offending websites and seizure of illegal medicines and medical devices worldwide.

The action occurred as part of the Eighth Annual International Internet Week of Action (IIWA), a global cooperative effort, led by INTERPOL, to combat the unlawful sale and distribution of illegal and potentially counterfeit medical products on the Internet. Continue reading

BIO Releases Paper Encouraging Industry to Include the Patient Voice Early in Drug Discovery

Washington, DC, June 21, 2015 Biotechnology Industry Organization (BIO) this week released a white paper, “A Lifecycle Approach to Structured Benefit/Risk Assessment Framework,” to encourage companies to incorporate and reflect patient preferences throughout the drug development lifecycle.

“The voice of patients can play a critical role in helping to better inform the search for treatments and cures for chronic and deadly diseases throughout drug discovery and development,” said Kay Holcombe, Senior Vice President for Science Policy at BIO. Continue reading

U.S. House Votes to Kill Obamacare’s 2.3 Percent Medical Device Tax

Washington, DC, June 19, 2015 The New York Times reported that the U.S. House of Representatives defied a White House veto threat and voted Thursday to abolish a tax on medical device makers as a group of Democrats uncharacteristically joined Republicans in moving to kill part of President Obama’s health care law.

Thursday’s 280-140 House vote was exactly the two-thirds margin that supporters would need to override a presidential veto.

The real suspense will come in the Senate, which voted overwhelmingly to repeal the levy in 2013, but in a nonbinding roll call lacking the political pressures of a veto showdown. Continue reading

Governor, Lt. Governor, Industry Leaders Promote NJ Life Sciences in ChooseNJ Video

Video ChooseNJ 20150618Philadelphia, PA, June 18, 2015 Choose New Jersey premiered a new video — “Leaders Choose New Jersey: Highly Educated, Perfectly Located” — at the 2015 BIO International Convention, which was held June 15-18 at the Philadelphia Convention Center.

Those New Jersey leaders appearing in the video to promote the state as a winning place for life sciences companies to invest are:

  • Governor Chris Christie
  • Lt. Governor and Secretary of State Kim Guadagno
  • Michele Brown, President and Chief Executive Officer, Choose New Jersey
  • Debbie Hart, President and Chief Executive Officer, BioNJ

To view the 4:17-minute video, click here. Continue reading

New Jersey Assemblywoman Lampitt Honored as BIO State Legislator of the Year

Pam LampittPhiladelphia, PA, June 18, 2015 ― The Biotechnology Industry Organization (BIO) announced its selection of New Jersey State Assemblywoman Pamela Lampitt (6th District) as a state Legislator of the Year for 2015.

Assemblywoman Lampitt is the prime sponsor of A-2477, which authorizes the prescription and dispensing of biosimilar products in New Jersey.  Assemblywoman Lampitt received this honor during the 2015 BIO International Convention, which was held this week in Philadelphia. Continue reading

Amy Mansue, Head of Children’s Specialized Hospital, Is New Chair of N.J. Chamber of Commerce

Amy_Mansue - CopyTrenton, NJ, June 17, 2015 ― Amy Mansue, president & CEO of Children’s Specialized Hospital, has been named Chair of the New Jersey Chamber of Commerce Board of Directors. The move was confirmed by the Chamber Board on June 10. Mansue will serve a two-year term.

Mansue has been serving as the N.J. Chamber’s first vice chair for the past two years and has been a member of the Chamber’s Board of Directors since 2004.

Mansue succeeds Ralph Izzo, chairman and CEO of Public Service Enterprise Group Inc. (PSEG). Continue reading

Biotechnology Industry Organization to Become Biotechnology Innovation Organization

Philadelphia, PA, June 17, 2015 ― BIO’s new Board Chair, Ron Cohen, CEO of Acorda Therapeutics, announced during Wednesday afternoon’s Keynote Luncheon of the 2015 BIO International Convention that the Biotechnology Industry Organization would soon become the Biotechnology Innovation Organization.

Cohen, in his first remarks as BIO’s new Board Chair, said, “I’m pleased to announce that the BIO Board has approved a change to BIO’s name… from the Biotechnology Industry Organization to the Biotechnology Innovation Organization. Still BIO, but now with a name that better expresses the essence of what our member companies represent.” Continue reading

EY’s Annual Biotechnology Industry Report: Global Biotech Sizzlesas Market Capitalization Surpasses US$1 Trillion

Philadelphia, PA, June 16, 2015 ― The global biotechnology industry reached new heights in 2014, setting records on virtually every major financial metric, including revenues, profitability and capital raised, according to “Beyond Borders: Reaching New Heights,” EY’s 29th Annual Biotechnology Industry Report.

These positive performance indicators, combined with several high-profile product successes and a strong year for new drug approvals, drove the industry’s total market capitalization above the US$1 trillion threshold for the first time in its history. Continue reading

BIO 2015 Kicks Off Today; New Jersey to Showcase Life Science Leaders, Innovations at BIO International Convention

BIO International Convention LOGOTrenton, NJ, June 15, 2015 ― New Jersey will showcase its business strengths in the life science industry to a global audience next week at the world’s largest biotechnology conference, the 2015 BIO International Convention, being held at the Philadelphia Convention Center on June 15-18.

More than 15,000 attendees are expected to attend this year’s BIO International Convention, which regularly attracts thousands of the most powerful and influential biotech and pharma players from all over the world.

Representatives from more than 65 countries will participate in business partnering and networking to share ideas and discuss new innovations in the industry. Continue reading